Author

M. Clementi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 4 Immunology· 2 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Organism:human· 5 Research Focus:host-pathogen & immune response· 4 Assay:bulk RNA-seq· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Assay:proteomics· 2 Approach:statistical model· 2

Frequent Co-Authors

N. Mancini· 6 shared N. Clementi· 5 shared E. Criscuolo· 4 shared M. Castelli· 3 shared R. A. Diotti· 3 shared E. Vicenzi· 2 shared I. Pagani· 2 shared R. Burioni· 2 shared

Activity by Year

2020-2021 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersMicrobiology

N. Mancini

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

SARS-CoV-2 Spike Affinity and Dynamics Exclude the Strict Requirement of an Intermediate Host

M. Castelli, L. Scietti, N. Clementi, M. Cavallaro, S. Faravelli, A. Pinnola, E. Criscuolo, R. A. Diotti, M. Clementi, F. Forneris, N. Mancini

This study shows SARS-CoV-2 and RaTG13 spikes have similar ACE2 binding affinities, suggesting minimal species barriers, and highlights SARS-CoV-2's optimized dynamics for human ACE2 engagement.

bioRxiv · Aug 11, 2021 · PreprintMicrobiology

Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection

M. Severa, R. A. Diotti, M. P. Etna, F. Rizzo, S. Fiore, D. Ricci, M. Iannetta, A. Sinigaglia, A. Lodi, N. Mancini, E. Criscuolo, M. Clementi, M. Andreoni, S. Balducci, L. Barzon, , E. Coccia

This study compares plasmacytoid dendritic cell (pDC) phenotype and type I IFN response in asymptomatic and severe COVID-19 patients, finding differences in pDC frequency, phenotype, and cytokine levels.

bioRxiv · Apr 17, 2021Immunology

Severity of SARS-CoV-2 infection as a function of the interferon landscape across the respiratory tract of COVID-19 patients.

B. Sposito, A. Broggi, L. Pandolfi, S. Crotta, R. Ferrarese, S. Sisti, N. Clementi, A. Ambrosi, E. Liu, V. Frangipane, L. Saracino, L. Marongiu, F. Facchini, A. Bottazzi, T. Fossali, , I. Zanoni

This study examines IFN-I and IFN-III expression patterns in the respiratory tract of COVID-19 patients, finding higher IFN-III levels in severe cases and varying roles across anatomical sites.

bioRxiv · Mar 30, 2021 · PreprintImmunology

A human stem cell-derived neurosensory-epithelial circuitry on-a-chip to model herpes simplex virus reactivation

P. G. Mazzara, E. Criscuolo, M. Rasponi, L. Massimino, S. Muggeo, C. Palma, M. Castelli, M. Clementi, R. Burioni, N. Mancini, V. Broccoli, N. Clementi

This study develops a human stem cell-derived neurosensory-epithelial circuitry on-a-chip to model HSV-1 reactivation and latency.

bioRxiv · Nov 19, 2020Microbiology

Vinegar and Its Active Component Acetic Acid Inhibit SARS-CoV-2 Infection In Vitro and Ex Vivo

I. Pagani, S. Ghezzi, M. Clementi, G. Poli, M. Bussi, L. Pianta, M. Trimarchi, E. Vicenzi

This study shows vinegar and acetic acid inhibit SARS-CoV-2 infection in vitro and ex vivo, with enhanced effects at 45°C.

bioRxiv · Jul 8, 2020Microbiology

Heparin inhibits cellular invasion by SARS-CoV-2: structural dependence of the interaction of the surface protein (spike) S1 receptor binding domain with heparin.

C. Mycroft-West, D. Su, I. Pagani, T. Rudd, S. Elli, S. Guimond, G. Miller, M. Meneghetti, H. Nader, Y. Li, Q. Nunes, P. Procter, N. Mancini, M. Clementi, A. Bisio, , M. A. Skidmore

This study shows heparin inhibits SARS-CoV-2 invasion by binding to the Spike protein's RBD and inducing conformational changes, with structural features of heparin playing a key role.

bioRxiv · Apr 28, 2020Biochemistry

Combined prophylactic and therapeutic use maximizes hydroxychloroquine anti-SARS-CoV-2 effects in vitro

N. Clementi, E. Criscuolo, R. A. Diotti, R. Ferrarese, M. Castelli, R. Burioni, M. Clementi, N. Mancini

This study shows that hydroxychloroquine is most effective against SARS-CoV-2 when used both before and after infection in vitro.

bioRxiv · Mar 29, 2020Microbiology